Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Systemic autoimmune and chronic inflammatory diseases are a group of chronic illnesses whose treatment is usually very prolonged, often lifelong, and is essential to keep the disease under control, thus reducing the risk of complications and allowing the best possible quality of life for patients.
The drugs used for treating these diseases are mostly immunosuppressants, which reduce the activity of the immune system, whose alteration is responsible for the disease. Although all available drugs are effective for treating these diseases, for reasons largely unknown, each drug is effective only in a percentage of patients. As a result, it is often necessary to try several different treatments before identifying an effective one for the individual patient.
The therapeutic effects are often slow, and it is therefore necessary to take a treatment for weeks or months before its effectiveness can be determined. The initial period is also when side effects most often appear. The aim of this study is to evaluate whether the addition of remote monitoring visits and other patient support services to traditional periodic medical visits in the first months after the introduction of a new treatment leads to an improvement in adherence, response, and quality of life for the patient.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Remote Monitoring | Experimental |
| |
| On site only | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Remote Monitoring | Other | Follow-up at outpatient clinic at 3 and 6 months from drug prescription Two remote consultations at 15 and 45 days from drug prescription |
|
| Measure | Description | Time Frame |
|---|---|---|
| Treatment persistence | Percentage of patients taking the same medication prescribed at baseline | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Treatment Persistence | Percentage of patients taking the same medication prescribed at baseline | 3 months |
| Disease activity score on 28 joints with C-Reactive Protein (DAS28-CRP) | Only applies to rheumatoid arthritis patients |
Not provided
Inclusion Criteria:
Any patient with one of the following conditions
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Rheumatology Unit - Perugia Univeristy Hospital | Recruiting | Perugia | PG | 06129 | Italy |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| On site monitoring | Other | Follow-up at outpatient clinic at 3 and 6 months from drug prescription. |
|
| 3 months |
| Disease activity score on 28 joints with C-Reactive Protein (DAS28-CRP) | Only applies to rheumatoid arthritis patients | 6 months |
| Psoriatic Arthritis Disease Activity Score (PASDAS) | Only applies to psoriatic arthritis patients | 3 months |
| Psoriatic Arthritis Disease Activity Score (PASDAS) | Only applies to psoriatic arthritis patients | 6 months |
| Body Surface Area (BSA) | Percentage of skin surface with psoriatic lesions. Only applies to psoriatic arthritis patients | 3 months |
| Body Surface Area (BSA) | Percentage of skin surface with psoriatic lesions. Only applies to psoriatic arthritis patients | 6 months |
| Minimal Disease Activity (MDA) | Binary outcome. Only applies to psoriatic arthritis patients | 3 months |
| Minimal Disease Activity (MDA) | Binary outcome. Only applies to psoriatic arthritis patients | 6 months |
| Modified Rodnan's skin score | Only applies to systemic sclerosis patients | 3 months |
| Modified Rodnan's skin score | Only applies to systemic sclerosis patients | 6 months |
| Medical Research Council (MRC) dyspnoea scale | Only applies to systemic sclerosis patients with interstitial lung disease | 3 months |
| Medical Research Council (MRC) dyspnoea scale | Only applies to systemic sclerosis patients with interstitial lung disease | 6 months |
| EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) | Only applies to Sjogren's disease patients | 3 months |
| EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) | Only applies to Sjogren's disease patients | 6 months |
| EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) | Only applies to Sjogren's disease patients | 3 months |
| EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) | Only applies to Sjogren's disease patients | 6 months |
| Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)-2K | Only applies to systemic lupus erythematosus patients | 3 months |
| Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)-2K | Only applies to systemic lupus erythematosus patients | 6 months |
| Ankylosing Spondylitis Disease Activity Score (ASDAS) | Only applies to ankylosing spondylitis and axial spondyloarthritis patients | 3 months |
| Ankylosing Spondylitis Disease Activity Score (ASDAS) | Only applies to ankylosing spondylitis and axial spondyloarthritis patients | 6 months |
| Health Assessment Questionnaire Disability Index (HAQ-DI) | Range 0 (best condition) - 3 (worst condition) | 3 months |
| Health Assessment Questionnaire Disability Index (HAQ-DI) | Range 0 (best condition) - 3 (worst condition) | 6 months |
| Anxiety and Depression | Hospital Anxiety and Depression Scale - Anxiety and Depression range 0 - 21 each (higher values mean higher degrees of depression or anxiety) | 3 months |
| Anxiety and Depression | Hospital Anxiety and Depression Scale - Anxiety and Depression range 0 - 21 each (higher values mean higher degrees of depression or anxiety) | 6 months |
| EQ-5D-5L score | The score measures quality of life and includes 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each of which is scored from 1 (perfect health) to 5 (complete inability). | 3 months |
| EQ-5D-5L score | The score measures quality of life and includes 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each of which is scored from 1 (perfect health) to 5 (complete inability). | 6 months |
| Number of phone calls to Rheumatology Outpatient Clinic | 6 months |
| Number of additional, unscheduled rheumatology consultations | 6 months |
| Number of consultations to GP due to prescribed treatment-related issues | 6 months |
| ID | Term |
|---|---|
| D001172 | Arthritis, Rheumatoid |
| D015535 | Arthritis, Psoriatic |
| D008180 | Lupus Erythematosus, Systemic |
| D012595 | Scleroderma, Systemic |
| D000089183 | Axial Spondyloarthritis |
| D013167 | Spondylitis, Ankylosing |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
| D003240 | Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D025242 | Spondylarthropathies |
| D025241 | Spondylarthritis |
| D013166 | Spondylitis |
| D013122 | Spinal Diseases |
| D001847 | Bone Diseases |
| D011565 | Psoriasis |
| D017444 | Skin Diseases, Papulosquamous |
| D012871 | Skin Diseases |
| D000844 | Ankylosis |
Not provided
Not provided
| ID | Term |
|---|---|
| D000098465 | Remote Patient Monitoring |
| ID | Term |
|---|---|
| D017216 | Telemedicine |
| D003695 | Delivery of Health Care |
| D010346 | Patient Care Management |
| D006298 | Health Services Administration |
Not provided
Not provided